Wěi Li

74.2k citations
1.4k papers · 45.9k · 12 hit papers · h-index 90

Impact in

  • Cancer Research top 0.05%
    • Cancer, Hypoxia, and Metabolism
    • MicroRNA in disease regulation
    • Cancer-related molecular mechanisms research
  • Oncology top 0.1%

Papers in

    • Cancer therapeutics and mechanisms 58
    • HER2/EGFR in Cancer Research 57
    • Cancer-related Molecular Pathways 40

Wěi Li

1.4k papers receiving 45.3k citations

Wěi Li's Hit Papers

Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial 2025 · 22 citations
220+5+10Years since publication50010001.5k2.0k

Peers

Wěi Li
Comparison fields: 5 of 206
  • Cancer Research 5.7k
  • Oncology 8.3k
  • Pathology and Forensic Medicine 4.2k
  • Molecular Biology 16.7k
  • Pulmonary and Respiratory Medicine 5.2k
Replace Masayuki Yamamoto with:
Masayuki Yamamoto Japan
Michael B. Sporn United States
Roger J. Davis United States
Christopher K. Glass United States
Peter Libby United States
Toren Finkel United States
Lorenzo Galluzzi France
Chen Chen China
John C. Reed United States
Dean P. Jones United States
Wěi Li relative to Masayuki Yamamoto Japan Masayuki Yamamoto's profile →
Citations per field
00.5×1.5×1.8×
Masayuki Yamamoto · 1×
Citations per year

Countries citing papers authored by Wěi Li

Since Specialization
Citations

This map shows the geographic impact of Wěi Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wěi Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wěi Li more than expected).

Fields of papers citing papers by Wěi Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wěi Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wěi Li. The network helps show where Wěi Li may publish in the future.

Co-authors

The 25 scholars most cited alongside Wěi Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Wěi Li Line = papers co-authored together Wěi Li links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 1.4k papers — load more, or switch the sort, to bring in the rest.

#Work
1
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Hit paper breakdown →
20172221
2
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Hit paper breakdown →
20141589
3
HIF-1α pathway: role, regulation and intervention for cancer therapy
Hit paper breakdown →
20151493
4
An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
Hit paper breakdown →
2012634
5
Quantitative susceptibility mapping of human brain reflects spatial variation in tissue composition
Hit paper breakdown →
2011513
6 2015385
7 2009369
8 2009329
9
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
Hit paper breakdown →
2015325
10
Steroidogenesis in the skin: Implications for local immune functions
Hit paper breakdown →
2013295
11 2010267
12 2019265
13 2009259
14 2014258
15 2019253
16 2001249
17 2012247
18 2014245
19 2015213
20 2013210

About Wěi Li

Wěi Li is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Organic Chemistry, having authored 1.4k papers that have together received 45.9k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (63 papers), Synthesis and biological activity (61 papers), Cancer therapeutics and mechanisms (58 papers), HER2/EGFR in Cancer Research (57 papers), Vitamin D Research Studies (51 papers), Estrogen and related hormone effects (50 papers), Click Chemistry and Applications (46 papers) and Cancer-related Molecular Pathways (40 papers). The work is most often cited by research in Cancer Research (5.7k citations), Oncology (8.3k citations), Pathology and Forensic Medicine (4.2k citations), Molecular Biology (16.7k citations) and Pulmonary and Respiratory Medicine (5.2k citations). Wěi Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Duane D. Miller, Andrzej Słomiński, Robert C. Tuckey, Chunlei Liu, Tae‐Kang Kim, Jianjun Chen, Bing Wu, Yan Lü, Zorica Janjetović and Jin Wang. Their work appears in journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry, Cancer Research, PLoS ONE and Frontiers in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact